Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026
Key Highlights
- ➤STX-1150 prototype lowered LDL-C up to 68% in non-human primates
- ➤STX-1150 sustained over 50% LDL-C reduction for two years
- ➤STX-1150 repeat dosing progressively lowered LDL-C while maintaining tolerability
- ➤STX-1200 surrogate cut circulating Apo(a) by over 95% at 10 weeks
- ➤STX-1200 achieved over 80% hepatic LPA editing without detected off-target activity
Expert Statements
Benjamin L. Oakes, Co-founder and CEO of Scribe Therapeutics
“We believe that a majority of heart attacks could be prevented if patients and providers were able to proactively, easily, and sustainably reduce lipids that drive ASCVD.”
Benjamin L. Oakes, Co-founder and CEO of Scribe Therapeutics
“Our AHA data reinforce the potential for purpose-built CRISPR medicines to transform chronic cholesterol management and bring us closer to our vision of making the protective benefits of human genetics accessible to millions of patients.”
Single dose of STX-1150 prototype lowered LDL-C by >50% for at least two years in non-human primates without permanent DNA modification, supporting the potential for ultra-long-acting cholesterol control with reduced treatment burden; repeat dosing in NHPs enabled further LDL-C lowering while maintaining tolerability
STX-1200 surrogate achieved >95% Lp(a) reduction in non-human primates, without detectable off-target editing in primary human hepatocytes, reinforcing the potential for a potent and precise one-time Lp(a)-lowering therapy designed to recapitulate genetic protection of low Lp(a)
Get started
Create a free account to read the full story.
